EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)

@article{Tennvall2007EANMPG,
  title={EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin)},
  author={Jan Tennvall and Manfred Fischer and Angelika Bischof Delaloye and Emilio Bombardieri and Lisa Bodei and Francesco Giammarile and Michael Lassmann and Wim J. G. Oyen and Boudewijn T. Brans},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2007},
  volume={34},
  pages={616-622}
}
BackgroundIn January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin’s lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin… 
Consensus conference on the use of 90‐yttrium‐ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology
TLDR
90 Y-ibritumomab-tiuxetan as a single agent has activity in relapsed/refractory mantle cell lymphoma and DLBCL, but the responses are of short duration, and its use after first line chemoimmunotherapy as consolidation therapy appears promising, particularly in elderly patients.
Radioimmunotherapy for B-cell non-Hodgkin lymphoma.
TLDR
These anti-CD20 RICs are active in patients who are refractory to single-agent rituximab, documenting the added value of the conjugated radioisotope.
Diagnostic imaging prior to 90Y-ibritumomab tiuxetan (Zevalin) treatment in follicular non-Hodgkin's lymphoma.
  • A. Otte
  • Medicine
    Hellenic journal of nuclear medicine
  • 2008
TLDR
It is shown in this article why a prediagnostic imaging or dosimetry is not necessary as an additional mandatory safety measure to confirm the expected biodistribution.
Dosimetry of 90Y-Ibritumomab Tiuxetan as Consolidation of First Remission in Advanced-Stage Follicular Lymphoma: Results from the International Phase 3 First-Line Indolent Trial
TLDR
In patients with low or minimal residual tumor burden after first-line chemotherapy of advanced FL, whole-body and bone marrow exposure after 90Y-ibritumomab tiuxetan consolidation showed a significant positive correlation with progression-free survival, whereas dosimetric data could not predict hematologic toxicity.
Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: efficacy and safety in a routine setting.
TLDR
The use of RIT-Z as a consolidation for pre-treated patients with both indolent and aggressive lymphoma is encouraged, with no long-term remissions observed in 7 patients who had not responded to their most recent therapy.
Radioimmunotherapy and Autologous Stem-Cell Transplantation in the Treatment of B-Cell Non-Hodgkin Lymphoma.
TLDR
Radioimmunotherapy is a form of targeted therapy using the parent monoclonal antibody to deliver radiation emitted by a conjugated radioisotope, to the vicinity of antigen-positive tissues, thus it can safely replace total-body irradiation during conditioning for ASCT.
Yttrium 90 ibritumomab tiuxetan (Zevalin®): A new bullet in the fight against malignant lymphoma?
TLDR
Zevalin is a commercially available variation of the murine anti‐CD20 antibody ibritumomab coupled to Yttrium 90 via the tiuxetan chelator as well as the results of the pivotal studies and clinical strategies to implement this treatment into the routine practice of lymphoma oncology are presented.
Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma
TLDR
D dose escalation of RIT and combined use with RIC is feasible with no additional toxicity due to dose escalation, and no directly RIT-related toxicities were observed.
High-Dose Radioimmunotherapy with 90Y-Ibritumomab Tiuxetan: Comparative Dosimetric Study for Tailored Treatment
TLDR
Dosimetric findings for 3 different methods are reported, including image corrections and actual organ mass corrections, to identify the most reliable and feasible dosimetric method to be adopted in high-dose therapy with 90Y-ibritumomab tiuxetan.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
[Guideline for radioimmunotherapy of rituximab relapsed or refractory CD20(+) follicular B-cell non-Hodgkin's lymphoma].
TLDR
This guideline is a prerequisite for the quality management in the treatment of non-Hodgkin-lymphomas using radioimmunotherapy and contains background information and definitions as well as specified indications and detailed contraindications of treatment.
Report of a European consensus workshop to develop recommendations for the optimal use of (90)Y-ibritumomab tiuxetan (Zevalin) in lymphoma.
  • A. Hagenbeek, V. Lewington
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
TLDR
Radioimmunotherapy (RIT) is a novel modality for treating indolent NHL, using monoclonal antibodies to target tumour cells with systemic, low-dose radiation with the aim of preventing recurrence.
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Y-labeled anti-CD20 monoclonal antibody.
TLDR
In summary, Y-ibritumomab tiuxetan introduces (90)Y into clinical practice and expands the role nuclear medicine plays in the care of patients with cancer.
Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody.
TLDR
It is essential for nuclear medicine physicians to be aware of, and know how to deal with, possible side effects during infusion and during the first hours after infusion of either the unlabeled or the labeled antibodies.
Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma.
  • T. Witzig, C. White, +5 authors P. Multani
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
TLDR
Single-dose (90)Y ibritumomab tiuxetan RIT has an acceptable safety profile in relapsed NHL patients with less than 25% lymphoma marrow involvement, adequate marrow reserve, platelets greater than 100,000 cells/micro L, and neutrophils greater than 1,500 cells/ micro L.
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
TLDR
These phase I/II data demonstrate that IDEC-Y2B8 radioimmunotherapy is a safe and effective alternative for outpatient therapy of patients with relapsed or refractory NHL.
Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
  • M. Juweid
  • Medicine
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 2002
TLDR
The basic concepts of RIT are reviewed with important milestones in its development for B-cell NHL treatment and particular emphasis on phase II and III clinical trials establishing its efficacy in clearly defined patient populations.
Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma
  • T. Witzig
  • Medicine
    Cancer Chemotherapy and Pharmacology
  • 2001
TLDR
90Y-ibritumomab tiuxetan radioimmunotherapy is a useful new treatment modality for patients with B cell NHL and the combination of the 90Y radioisotope to the murine anti-CD20 antibody provided additional efficacy over the unconjugated ("cold") rituximab alone.
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
  • T. Witzig, L. Gordon, +10 authors C. White
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
  • T. Witzig, I. Flinn, +8 authors C. White
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients and the only significant toxicity is hematologic.
...
1
2
3
4
...